RespireRx Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of RespireRx Pharmaceuticals generated cash of -$143,905, which is more than the previous year. Cash used in financing activities reached the amount of $142,595 last year. Net change in cash is therefore -$1,310.
Cash Flow
| 2013 | -182.43K | 0 | 44.60K |
|---|---|---|---|
| 2014 | -885.86K | -18.4K | 1.05M |
| 2015 | -1.29M | -2.49K | 1.18M |
| 2016 | -1.32M | 0 | 1.36M |
| 2017 | -697.00K | 0 | 689.87K |
| 2018 | -427.36K | 0 | 375.75K |
| 2019 | -487.74K | 0 | 471.15K |
| 2020 | -513.00K | 0 | 497.13K |
| 2021 | -956.17K | 0 | 956.74K |
| 2022 | -143.90K | 0 | 142.59K |
RSPI Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.39K | 825 | 16.69K | 33.28K | 84.90K | 92.04K | 53.19K | 162.75K | 14.35K | 152.17K |
Operating activities | ||||||||||
Net income | -2.10M | -3.14M | -4.30M | -2.11M | -2.59M | -4.29M | -9.22M | -5.96M | -2.70M | -1.20M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 552.78B | 374.08B | 215.57B | 8.37B | 5.16K | 6.95K | 7.11K | 1.65K | 0 |
Stock-based compensation expense | 0 | 58.75K | 384.25K | 779.40B | 0 | 4.50M | 4.73M | 2.70M | 3.23M | 595.08K |
| Deferred income tax benefit | 0 | 58.75K | 384.25K | 779.40B | 0 | 4.50M | 4.73M | 2.70M | 3.23M | 595.08K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 48K | -48K | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -29.33K | 0 |
Accounts payable | 482.28K | 605.82K | 1.26M | 524.32K | 703.68K | 476.44K | 1.22M | 490.38K | 452.09K | 321.77K |
Cash generated by operating activities | -143.90K | -956.17K | -513.00K | -487.74K | -427.36K | -697.00K | -1.32M | -1.29M | -885.86K | -182.43K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 5 | 0 | 0 | 0 | 0 | 0 | 0 | -2.49K | -18.4K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.49K | -18.4K | 0 |
Financing activities | ||||||||||
Common Stock Issued | 0 | 117.29K | 162.88K | 0 | 0 | 754.5K | 0 | 1.19M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -1.29K | 0 | 0 | 0 |
Repayments of term debt | 24.81K | -828.86K | -334.25K | 500.90K | 0 | -64.62K | 0 | 114.84K | 0 | 0 |
Cash used in financing activities | 142.59K | 956.74K | 497.13K | 471.15K | 375.75K | 689.87K | 1.36M | 1.18M | 1.05M | 44.60K |
Net Change In Cash | -1.31K | 573 | -15.86K | -16.59K | -51.61K | -7.13K | 38.84K | -109.55K | 148.4K | -137.82K |
Cash at end of period | 88 | 1.39K | 825 | 16.69K | 33.28K | 84.90K | 92.04K | 53.19K | 162.75K | 14.35K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |